Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

By W. Sandborn, B. Feagan, C. Marano, Hongyan Zhang, R. Strauss, J. Johanns, O. Adedokun, C. Guzzo, J. Colombel, W. Reinisch and 4 more. Gastroenterology, 2014

718 citations recorded by the source corpus.

Subfields: Complementary and alternative medicine, Genetics, Rheumatology

View Paper: https://www.semanticscholar.org/paper/35eab88d7c9f3e0f6b0951d1fe3e39e758463137